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686Epidemiology of peripheral arterial disease and
critical limb ischemia in an insured national
population
Mark R. Nehler, MD,a Sue Duval, PhD,b Lihong Diao, MS,c Brian H. Annex, MD,d William R. Hiatt, MD,e
Kevin Rogers, MD,e Armen Zakharyan, PhD,f and Alan T. Hirsch, MD,g Aurora, Colo; Minneapolis, Minn;
and Charlottesville, Va
Background: Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease
(PAD) and is the major cause of ischemic amputation in the United States. Risk factors and the associated incidence and
prevalence of CLI have not been well described in the general population. This study describes the risk factors for PAD
progression to CLI and estimates the annual incidence and prevalence of CLI in a representative United States patient
cohort.
Methods: This was a retrospective cohort analysis of adults with commercial, Medicare supplemental, or Medicaid health
insurance who had at least one PAD or CLI health care claim from January 1, 2003, through December 31, 2008, and
12 months of continuous coverage. Two subgroups of CLI presentation were identiﬁed: primary CLI (patients without
any prior PAD or subsequent PAD diagnostic code >30 days after CLI diagnostic code) and secondary CLI (patients with
prior PAD or subsequent PAD diagnostic codes #30 days of a CLI diagnostic code). Patterns of presentation, annual
incidence, and prevalence of CLI were stratiﬁed by health care plan. Risk factors for progression to CLI were compared by
presentation type.
Results: From 2003 to 2008, the mean annual incidence of PAD was 2.35% (95% conﬁdence interval [CI], 2.34%-2.36%)
and the incidence of CLI was 0.35% (95% CI, 0.34%-0.35%) of the eligible study population, with primary and secondary
presentations occurring at similar rates. The mean annualized prevalence of PAD was 10.69% (95% CI, 10.67%10.70%)
and the mean annualized prevalence of CLI was 1.33% (95% CI, 1.32%-1.34%) of the eligible study population, and two-
thirds of the cases presented as secondary CLI. CLI developed in 11.08% (95% CI, 11.30%-11.13%) of patients with PAD.
A multivariable model demonstrated that diabetes, heart failure, stroke, and renal failure were stronger predictors of
primary rather than secondary CLI presentation.
Conclusions: These data establish new national estimates of the incidence and prevalence of CLI and deﬁne key risk factors
that contribute to primary or secondary presentations of CLI within a very large contemporary insured population cohort
in the United States. (J Vasc Surg 2014;60:686-95.)Although the prevalence of peripheral arterial disease
(PAD) has been evaluated in several epidemiologic
studies,1-3 major knowledge gaps exist for critical limb
ischemia (CLI). The population prevalence of PAD can
be easily studied using standard epidemiologic approaches,
with the ankle-brachial index serving as an objective mea-
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extremity features, including ischemic rest pain and non-
healing ischemic wounds or gangrene, and requires the
objective measurement of ankle or toe pressures. Few prior
population-based studies have used such symptom and
examination-based clinical criteria to deﬁne CLI incidence
or prevalence.6 Thus, in the absence of such data, establish-
ing reliable estimates of the incidence and prevalence of
CLI or demonstrating temporal incidence trends has
been difﬁcult.7,8
Current United States and international PAD practice
guidelines have suggested that the annual incidence of
CLI is 500 to 1000 cases/million people, but these esti-
mates were largely based on older regional cohorts and
limited survey studies of European populations.9,10 In the
absence of a common methodologic approach, a major
CLI incidence and prevalence knowledge gap persists.
There are no data to support the presumption that PAD
follows a steady progression of severity and that few pa-
tients with claudication develop CLI.11 Conversely,
selected clinical cohort studies of patients with a history
of ischemic amputation or revascularization for CLI have
demonstrated a lack of any antecedent PAD symptoms or
diagnosis in roughly half of these patients.12-14 These ob-
servations have suggested that there may be different pat-
terns of CLI presentation.
Large administrative claims databases have been used
to examine a variety of trends in health care.15-25 These da-
tabases have deﬁned temporally increased rates of endovas-
cular revascularization, stable to declining amputation
rates, and racial and geographic vascular access health
care disparities.25,26 A recent study of the Medicare inpa-
tient and outpatient database demonstrated an annual
CLI incidence of 0.20% to 0.48% and an annual CLI prev-
alence of 0.23% to 0.54%, depending on a limited or
expanded use of codes to deﬁne the same.27 On the basis
of this background, this study used national administrative
claims database to examine estimates of PAD and CLI inci-
dence, prevalence, patterns of presentation, and risk factors
for progression to CLI.
METHODS
Study design and data source. A steering committee,
including vascular specialty clinicians with CLI expertise,
cardiovascular epidemiologists, and a biostatistician with
expertise in large claims database analysis, was established
to develop an independently managed protocol and statis-
tical analysis plan, to review and select codes for PAD and
CLI population identiﬁcation, and to conduct the analysis.
Authors A.H. and M.N., who were co-chairs for the
steering committee, were selected to oversee the conduct
of the study.
Data were obtained from the MarketScan database
(Thomson Reuters [Healthcare] Inc, New York, NY) span-
ning the years 2003 to 2008 that included commercial,
Medicare supplemental, and Medicaid populations. The
MarketScan database contains detailed health services re-
cords derived from a set of large employers’ health plansand from Medicare and Medicaid programs for millions
of patients residing in many states across the country. Mar-
ketScan links billing and encounters data to detailed patient
demographic and enrollment information across sites and
types of providers and includes commercial health data
from w100 payers. The strengths of the database are
that data are collected only when 100% of claims have
been paid, improving the accuracy. Potential biases are in-
clusion of only Medicare beneﬁciaries who have supple-
mental insurance coverage (and may have access to better
treatment), inclusion of employees only from large ﬁrms,
and a geographic distribution that favors the central and
southeastern United States.
In this retrospective cohort analysis, claims data for
eligible patients (aged $40 years) were examined from
2003 to 2008. Each individual PAD or CLI case was identi-
ﬁed on an “index diagnosis code date,” deﬁned as the ﬁrst
PAD or CLI diagnosis claim date identiﬁed in the period
from January 1, 2004, throughDecember 31, 2008. Further
stratiﬁcation was then applied to identify patients with a sta-
ble “prevalence period,” deﬁned as (1) a minimum 12-
month period of continuous health insurance enrollment
and (2) noPADorCLI diagnosis code before the index date.
Examining a run-in prevalence period in claims
research before the period during which the incidence is
determined has been shown to improve the distinction be-
tween incident and prevalent cases.28 Patients without an
adequate 12-month prevalence run-in period before their
PAD or CLI diagnosis code were excluded from further
analysis. The observation period for each patient started
on their “index diagnosis code date” and continued
through December 31, 2008. Prevalent PAD and CLI
cases were assessed beginning in 2003, with incident cases
assessed beginning in 2004 to incorporate the prevalence
period. Information was available on insurance enrollment,
age, sex, and inpatient and outpatient diagnosis and proce-
dure codes (Fig 1).
Code selection. Primaryor secondarydiagnosis Interna-
tional Classiﬁcation of Diseases, Ninth Revision (ICD-9)
codes and Current Procedural Terminology (CPT; American
Medical Association, Chicago, Ill) codes were selected via a
system designed to identify patients as having PAD with or
without CLI within the following nonexclusive clinical cate-
gories: (1) PAD-speciﬁc codes or combination of codes, (2)
CLI-speciﬁc codes or combinationof codes, (3) PADorCLI-
speciﬁc lower extremity revascularization codes, and (4)major
lower extremity amputation codes (Supplementary Table,
online only). The following method was used to select the
codes: First, ICD-9 and CPT coding manuals were used to
identify all potentially relevant CPT and ICD-9 codes. Next,
the steering committee reviewed the published PAD andCLI
literature to determine the frequency of previous codes used
to deﬁne claims-based PAD and CLI patients. From this re-
view, relevant combination codes were selected to be more
inclusive of probable PAD and CLI cases; for example, to
include patients treated for an “ulcer” in combination with
atherosclerosis, because this would not otherwise be captured
as being related to CLI.
Fig 1. Cohort assembly to deﬁne prevalent and incident study populations. CLI, Critical limb ischemia; PAD,
peripheral arterial disease.
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their overall contribution to the ﬁnal identiﬁed popula-
tion. A similar strategy to increase CLI coding yields
has been demonstrated previously.27 Final selection of
codes by steering committee members was designed to
be maximally inclusive of codes for atherosclerotic lower
extremity PAD and exclusive of codes that deﬁned acute
thrombosis or embolism, and arterial disease of the upper
extremity, carotid, and mesenteric arteries. These code
categories are presented in the Supplementary Table, on-
line only.
Index cases of PAD or CLI were deﬁned according
to the following clinical categories of codes: PAD, CLI,
lower extremity revascularization, and lower extremity
major amputation. Speciﬁc code linkage criteria were
further applied to deﬁne cases as PAD or CLI. Ischemic
rest pain was deﬁned exclusively using the speciﬁc code
for same (440.22) to exclude other causes of extremity
pain. Combination codes were used for CLI, as an
example, so that lower extremity wound codes were
included within the CLI clinical category only if present
in combination with subsequent ICD-9 codes that were
speciﬁc to lower extremity PAD (440.20, 440.21,
440.22, 440.23, and 440.24). Similarly, codes speciﬁc
to lower extremity revascularization were included within
the CLI clinical category only if present in combination
with more speciﬁc subsequent codes, such as atheroscle-
rosis with gangrene, ulceration, or rest pain (ICD-9
codes 440.24, 440.23, 440.22). All other revasculariza-
tion codes were included in the PAD (non-CLI)
category. Codes speciﬁc to major lower extremityamputation were considered stand-alone codes for CLI
and did not require linkage with an ICD-9 code speciﬁc
to atherosclerosis to be included in the CLI category. In
addition, cancer and trauma-related ICD-9 or CPT
codes were used to exclude non-CLI causes of leg
amputation.
Once the codes were identiﬁed, patients were assigned
into three mutually exclusive groups: PAD without having
an associated CLI code, PAD progressing to CLI (second-
ary CLI) where the CLI code occurred >30 days after the
PAD code, and primary CLI where the CLI code occurred
without a concomitant PAD code or the PAD code was
noted #30 days after the CLI code. Table I reports these
three patient study groupings for the described prevalent
and incident examples.
Patient characteristics and comorbidities. Study
population comorbidities, based on predeﬁned ICD-9
codes, were selected in a manner similar to the code se-
lection for PAD and CLI described above. Most comorbid
conditions were included if present before the index date of
PAD or CLI. However, diabetes was deﬁned as a baseline
comorbidity if present before the index date of PAD or
CLI or at any time during the observation period because
of the inherent discrepancy between the “onset” of dia-
betes and the imprecise timing of related ICD-9 codes in a
claims database.
Incidence and prevalence calculations. The annual
prevalence of PAD and CLI from 2003 to 2008 was calcu-
lated as the number of patients with PAD or CLI at a spe-
ciﬁc year, divided by the total eligible population during
that same year. The eligible population varied annually
Table I. Categorization of peripheral arterial disease (PAD) and critical limb ischemia (CLI) patientsa
Variable PADþ/CLIe (PAD)b
PADþ/CLIþ
(secondary CLI)c
PADe/CLIþ
(primary CLI)d Totale
Prevalent cases with any
code in 2004
PAD without CLI
(n ¼ 141,094) or
RV code without
amputation or wound
(n ¼ 8160)
PAD code and:
CLI code or
Amputation code or
RV and CLI code
CLI code or
Amputation code or
RV and CLI code
No. 149,254 11,563 7,732 168,549
PADþ/CLIe
(PAD)
PADþ/CLIþ
(secondary CLI)
PAD precedes CLI
PADe/CLIþ
(primary CLI)
CLI precedes PAD
Incident cases with
new codes from
2004-2008
Index event ﬁrst time
new PAD with no
CLI code
(n ¼ 183,110)
First time new RV
with no CLI code
(n ¼ 45,358)
Index event ﬁrst time
PAD code with
new CLI code
occurring
>30 days after
PAD code
(n ¼ 18,081)
Index event ﬁrst time
CLI (n ¼ 15,572)
without
concurrent PAD
code
Index event ﬁrst time
amputation
(n ¼ 2679)
without
concurrent PAD
code
No. 228,468 15,402 18,251 262,121
RV, Revascularization.
aBaseline prevalence was described in 2004, the ﬁrst year of the study.
bPADþ/CLIe is a PAD code without a CLI code (PAD).
cPADþ/CLIþ is a PAD code predating or #30 days after a CLI code (secondary CLI).
dPADe/CLIþ is a CLI code without a predating PAD code or subsequent PAD code #30 days subsequent to the CLI code (primary CLI).
eTotal is the sum of the three mutually exclusive vascular disease groups.
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who did not continue within their health insurance
coverage plan. The annual incidence was calculated as the
number of individuals with a new PAD or new CLI
ICD-9 or CPT code within the eligible population at risk
during a speciﬁc year, divided by the total eligible popu-
lation at risk at the beginning of the same year.
Statistical analysis. For all analyses, longitudinal data
sets with one record per individual from 2003 to 2008
were created. Descriptive statistics are presented with
continuous variables reported as mean values (standard
deviation) and categoric variables reported as propor-
tions. Estimates of PAD and CLI prevalence and inci-
dence are presented as percentages. Average prevalence
and incidence values were determined across the 6 years
of observation (with a 1-year baseline of continuous
coverage that was free of vascular disease) by using a
weighted averaging technique and are presented with
95% conﬁdence intervals (CIs).
Risk factors for primary and secondary CLI were ﬁrst
considered as univariate factors that included age, sex, dia-
betes, hypertension, obesity, myocardial infarction, stroke,
heart failure, and renal failure. Univariate associations
with a P value of <.10 were included in a multivariable
model adjusted for age and sex to predict which factors
were independently associated with developing CLI. Dataextraction and analysis was conducted using SAS 9.2 soft-
ware (SAS Institute Inc, Cary, NC).
RESULTS
Cohort assembly. Fig 2 shows the relative proportion
of major codes that served as contributors to the incident
PAD index case ascertainment: Almost three-quarters were
due to codes speciﬁc to “atherosclerosis” and “other pe-
ripheral vascular disease,” and 13% had a CLI code for
primary or secondary presentation. A breakdown of the
contribution to the two CLI presentation subgroups
showed most of the index cases for both were due to
atherosclerosis with ulceration, followed by atherosclerosis
and rest pain, and the remainder were due to atheroscle-
rosis and gangrene or atherosclerosis and amputation.
Amputation codes were more prominent in primary CLI
than in secondary CLI.
Baseline demographics and comorbidities in prev-
alent and incident populations. Baseline demographics
and comorbidities were derived from 2004, which was
the ﬁrst full year of patient identiﬁcation and follow-up.
Table II, A describes the incident population and Table II,
B the prevalent population. In the 2004 incident population,
age was similar across the three groups (Table II, A). Inci-
dent secondary CLI patients were more likely receiving
Medicaid than the PAD patients for the PAD and primary
Fig 2. Code distribution for peripheral arterial disease (PAD) and critical limb ischemia (CLI) subgroups. CPT,
Current Procedural Terminology (American Medical Association, Chicago, Ill); ICD-9, International Classiﬁcation of
Diseases, Ninth Revision.
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commercial insurance than secondary CLI patients. There
were no age differences among the three groups.
In 2004, the prevalent secondary CLI patients were
slightly older and more likely to be insured by Medicaid
than the PAD patients (Table II, B). In contrast, prevalent
primary CLI patients were younger and more likely to be
covered by commercial insurance than PAD patients. Prev-
alent patients who had secondary CLI had the highest
prevalence of cardiovascular risk factors, PAD was interme-
diate, and primary CLI had the lowest density of risk
factors.
Annual incidence of PAD and CLI in the study
population. Table III provides disease incidence by year
and type of coverage. The respective mean annual inci-
dence of PAD was 2.35% (95% CI, 2.34%-2.36%), sec-
ondary CLI was 0.16% (95% CI, 0.16%-0.16%), primary
CLI was 0.19% (95% CI, 0.18%-0.19%), and all CLI was
0.35% (95% CI, 0.34%-0.35%). The commercial insurance
population had a lower incidence of PAD and CLI than
individuals covered by Medicaid and Medicare.Annual prevalence of PAD and CLI in the study
population. Table IV provides disease prevalence by year
and type of coverage. The respective overall mean annual
prevalence of PAD was 10.69% (95% CI, 10.67%-10.7%),
secondary CLI was 0.86% (95%, CI 0.86%-0.87%), primary
CLI was 0.47% (95% CI, 0.46%-0.47%), and all CLI was
1.33% (95% CI, 1.32%-1.34%). All CLI represented
11.08% (95% CI, 11.03%-11.13%) of total PAD annually.
PAD and CLI prevalence was generally lower in patients
with commercial insurance than in those covered by
Medicaid and Medicare.
Risk factors for secondary CLI. Univariate predic-
tors for secondary CLI in patients with PAD included
age at time of PAD diagnosis, male gender, diabetes, and
a history of myocardial infarction, stroke, heart failure, or
renal failure (Table V). Hypertension was associated with
a decreased risk of developing secondary CLI. A multi-
variable model demonstrated an increased risk for sec-
ondary CLI was associated with diabetes (odds ratio [OR],
2.33), stroke (OR, 1.22), and heart failure (OR, 1.36),
with hypertension minimally lowering this risk (OR, 0.93).
Table II. A, Incidence population for peripheral arterial disease (PAD) and critical limb ischemia (CLI) subgroups:
baseline demographic characteristics and comorbidities of the study population in 2004 to 2008
Demographic characteristics
Incidence populationa
PADb (n ¼ 228,468) Secondary CLIc (n ¼ 15,402) Primary CLId (n ¼ 18,251) Totale (N ¼ 262,121)
Age, mean 6 SD years 68.9 6 12.5 69.3 6 12.6 69.0 6 13.4 68.9 6 12.6
Age group, years, %
40-49 6.4 6.4 7.9 6.5
50-59 19.3 19.2 20.4 19.4
60-69 25.3 23.8 22.7 25.0
70-79 12.1 12.2 10.6 12.0
80-84 24.8 25.7 23.4 24.8
$85 12.0 12.7 15.1 12.2
Gender, %
Male 43.7 47.8 46.1 44.1
Female 56.3 52.2 53.9 55.9
Type of health plan, %
Commercial 28.3 20.1 28.5 27.8
Medicaid 30.5 40.6 29.5 31.0
Medicare supplemental 41.2 39.3 42.0 41.2
Patients with $1
comorbidity, %
94.9 95.7 91.8 94.7
Diabetes 14.7 31.6 28.5 16.7
Hypertension 72.2 70.9 66.5 71.7
Myocardial infarction 43.3 41.8 34.5 42.6
Stroke 19.7 22.0 19.0 19.8
Heart failure 21.6 30.0 25.6 22.4
Renal failure 8.9 13.3 11.0 9.3
Cancer 14.5 9.6 11.3 14.0
SD, standard deviation.
aIncidence population: Adults $40 years with a PAD or CLI International Classiﬁcation of Diseases, 9th Revision (ICD-9) or Current Medical Terminology
(CPT; American Medical Association, Chicago, Ill) code in the MarketScan database (Thomson Reuters [Healthcare] Inc, New York, NY) between 2004 and
2008, and with continuous 12-month baseline coverage.
bIncident PAD deﬁned codes without CLI codes.
cIncident CLI deﬁned codes with a prior PAD diagnostic code and/or subsequent PAD code #30 days of CLI code.
dIncident CLI deﬁned codes without a prior PAD diagnostic code or subsequent PAD code #30 days of CLI code.
eTotal (PAD and CLI codes combined).
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for primary CLI in patients without PAD included age at
initial assessment, male gender, diabetes, hypertension,
and a history of myocardial infarction, stroke, heart failure,
or renal failure (Table VI). A multivariable model
demonstrated all of the univariate positive risk associations
remained statistically signiﬁcant, with diabetes being
markedly predictive (OR, 7.45).
DISCUSSION
These data establish new estimates of the annual inci-
dence and prevalence for PAD and CLI within the Market-
Scan database, a very large insured national population
surrogate. In the eligible population, PAD had an annual
incidence of 2.35% and an average annual prevalence of
10.69%, and CLI had an annual incidence of 0.35% and
an average prevalence of 1.33%. Annually, 11.08% of pa-
tients with PAD had CLI.
The PAD estimates from this insured population are
concordant with established population-derived data. The
incidence of CLI in this study is consistent with a recent
Medicare database report citing 0.2% to 0.4%, depending
on a narrow or broad range of code inclusion.27Conversely, it is signiﬁcantly higher than the incidence
rate reported as 220 cases/1 million people (0.022%) in
a large prospective population study29 and is also higher
than incidence rates cited in the TransAtlantic Inter-
Society Consensus for the Management of Peripheral Arte-
rial Disease (TASC II) guidelines of 500 to 1000/1
million people (0.05%-0.1%).30 The prevalence of CLI in
patients with PAD in this study is also slightly higher
than described in the TASC II guidelines (3%-10% over-
all).20 The TASC II guidelines data are derived from
data nearly 2 decades old and rely on surveys or longitudi-
nal data with small sample sizes for short periods of time
within deﬁned regional areas.6,10 In contrast, the current
analysis is based on a very large, geographically diverse na-
tional population and includes markedly greater numbers
of PAD and CLI individuals examined over a long
duration.
Finally, the prevalence of CLI in the current trial is
roughly three times greater than the 0.23% to 0.54% cited
in a recent Medicare database review.27 However, some of
this discrepancy could be explained by the exclusion of all
patients in the Medicare study without 12 months of
continuous follow-up data, which, given the annual
Table II. B, Prevalence population for peripheral arterial disease (PAD) and critical limb ischemia (CLI) subgroups:
baseline demographic characteristics and comorbidities of the study population in 2004
Demographic
characteristics
Prevalent populationa
PADb
(n ¼ 149,254)
Secondary CLIc
(n ¼ 11,563)
Primary CLId
(n ¼ 7732)
Total PADe
(N ¼ 168,549)
Age, mean 6 SD, years 68.9 6 12.5 69.7 6 12.6 66.3 6 13.9 68.9 6 12.6
Age group, years, %
40-49 7.2 6.4 12.6 7.4
50-59 17.7 17.1 23.3 17.9
60-69 24.3 24.0 21.9 24.2
70-79 13.4 12.9 10.2 13.2
80-84 26.5 26.5 20.1 26.2
$85 11.0 13.2 11.7 11.1
Sex, %
Male 46.4 52.6 48.7 46.9
Female 53.6 47.4 51.3 53.1
Type of health plan, %
Commercial 30.4 24.7 39.5 30.4
Medicaid 20.4 27.0 19.5 20.8
Medicare supplemental 49.2 48.3 41.0 48.8
Patients with $1
comorbidity, %
77.9 89.9 72.1 78.5
Diabetes 13.2 42.6 20.5 15.6
Hypertension 53.7 61.5 47.1 53.9
Myocardial infarction 33.6 42.3 23.4 33.8
Stroke 14.3 20.2 11.6 14.6
Heart failure 15.0 29.6 17.2 16.1
Renal failure 2.8 8.1 3.7 3.2
Cancer 8.6 7.3 7.8 8.5
SD, Standard deviation.
aPrevalent population: Adults $40 years with a PAD or CLI International Classiﬁcation of Diseases, 9th Revision (ICD-9) or Current Medical Terminology
(CPT; American Medical Association, Chicago, Ill) code in the MarketScan database (Thomson Reuters [Healthcare] Inc, New York, NY) in 2004 with
12 months of continuous eligible insurance coverage during the 2003 baseline period.
bPAD deﬁned codes without CLI codes.
cCLI deﬁned codes with a prior PAD diagnostic code or subsequent PAD code #30 days of CLI code, or both.
dCLI deﬁned codes without a prior PAD diagnostic code or subsequent PAD code #30 days of CLI code.
eTotal (PAD and CLI combined).
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current study. The current CLI prevalence is, however,
not markedly different than the pooled CLI prevalence of
0.8% in a recent meta-analysis.31 A study examining the
geographic breakdown of CLI prevalence did favor the
southeastern United States, which has biased representa-
tion in the MarketScan database.32
This study demonstrates that CLI prevalence was
higher in the Medicare and Medicaid cohorts compared
with the commercial payer population, consistent with
the increased age and comorbid diseases (eg, diabetes,
chronic kidney disease) that are present in these partic-
ular insured populations. The patterns of CLI coding
presentations were distinguished in the current study as
primary or secondary cases. That patients with claudica-
tion infrequently progress to CLI when followed up
longitudinally is well known.33 Prior small series of
CLI patients who undergo a revascularization procedure
or amputation have demonstrated that at least half of
these patients had no recognized PAD symptoms or
diagnosis in the 6 months before CLI presentation.28,29
These reports suggest that the presentation patterns ofCLI are not uniform. This study supports this concept,
because risk factors, presentation, and outcomes of indi-
viduals with the primary vs secondary presentations are
not identical.
Risk factors for secondary CLI were consistent with
previous CLI reports and support the critical role of
age, male gender, and pre-existing cardiovascular disease
as key predictors of a poor outcome of PAD. Risk factors
for primary CLI demonstrated stronger associations for
all risk factors, especially diabetes. This analysis could
imply a potential etiologic difference between individuals
who present with primary vs secondary CLI syndromes.
Hypertension, for example, was associated with a reduced
risk of developing secondary CLI, which is consistent with
prior data demonstrating that hypertension is sometimes
associated with improved foot perfusion and partially
ameliorating CLI symptoms. In contrast, hypertension,
as coded in our study, was associated with an increased
risk of developing primary CLI, and it is possible that
when hypertension is clinically recognized, treated phar-
macologically, and coded, this diagnosis may be associ-
ated with a lower risk of developing secondary CLI
Table III. Incidence of peripheral arterial disease (PAD) and critical limb ischemia (CLI) subgroups, overall and by
health insurance plan at each year (2004 to 2008)
Group Year Eligible risk population,a No.
Incidence
PAD,b % Secondary CLI,c % Primary CLI,d % Total,e %
Overall 2004 1,638,930 2.19 0.24 0.18 2.61
2005 1,744,766 2.83 0.23 0.23 3.29
2006 1,366,794 3.05 0.21 0.23 3.48
2007 2,275,054 1.83 0.10 0.14 2.07
2008 2,702,994 2.22 0.09 0.18 2.49
Mean (95% CI) 2.35 (2.34-2.36) 0.16 (0.16-0.16) 0.19 (0.18-0.19) 2.69 (2.68-2.70)
Commercial 2004 837,108 0.88 0.06 0.08 1.02
2005 848,702 1.50 0.09 0.13 1.72
2006 672,715 1.31 0.07 0.10 1.48
2007 1,472,776 0.81 0.03 0.06 0.91
2008 1,829,209 1.29 0.05 0.10 1.45
Medicaid 2004 278,509 4.99 0.71 0.40 6.10
2005 364,475 3.78 0.39 0.28 4.45
2006 318,395 5.66 0.43 0.43 6.52
2007 247,785 4.95 0.33 0.33 5.62
2008 251,551 4.65 0.26 0.42 5.34
Medicare
supplemental
2004 523,313 2.78 0.27 0.24 3.30
2005 531,589 4.30 0.33 0.35 4.98
2006 375,684 3.93 0.26 0.30 4.50
2007 554,493 3.13 0.17 0.26 3.56
2008 622,234 3.95 0.15 0.32 4.42
CI, Conﬁdence interval.
aAdults aged >40 years with commercial, Medicare supplemental, or Medicaid health insurance, without evidence of symptomatic PAD or CLI at any given
year between 2004 and 2008.
bTotal number of new PAD without CLI at a given year, divided by the eligible population at risk during the same year.
cTotal number of individuals with ﬁrst occurrence of an International Classiﬁcation of Diseases, 9th Revision (ICD-9) or Current Medical Terminology (CPT;
American Medical Association, Chicago, Ill) CLI code who also had a pre-existing PAD code or a subsequent PAD code #30 days in a given year, divided by
the eligible population at risk during the same year.
dTotal number of individuals with ﬁrst occurrence of an ICD-9 or CPT CLI code without a pre-existing PAD code or a subsequent PAD code #30 days.
eTotal number in all three groups (PAD, primary CLI, secondary CLI) in a given year, divided by the total number of individuals without evidence of
symptomatic PAD or CLI during the same year.
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and less PAD progression).
Limitations. This study has several limitations,
including the lack of independent validation of the codes
via medical record review. The analysis excluded large
numbers of patients due to lack of 12-month baseline
data, with possible bias due to mechanisms that cause
coverage change. However, these design features would all
result in an underestimation of CLI incidence and preva-
lence rates. Future analyses would also beneﬁt from
including an uninsured patient population.
The methodology used in this study may also over-
estimate CLI rates because of the effort to use an inclu-
sive list of billing codes. This is unique compared with
most of the coding literature on this subject that limits
CLI to the three codes linking atherosclerosis to rest
pain, ulceration, or gangrene. The use of all major am-
putations as a surrogate for CLI includes the minority
of amputations performed for diabetic neuropathy and
major foot infections with normal arterial circulation,
which may represent w10% of all major amputations
according to prior reviews.12,34 These assumptionswere used for the study to be maximally inclusive given
the relatively nonspeciﬁc nature of CLI administrative
coding.
The 30-day cutpoint to distinguish primary vs second-
ary CLI was arbitrary, and alternate cutpoints would shift
the fraction of individuals in each post hoc assigned CLI
category.
Major strengths of our study include the very large
sample, the rigorous review, and the selection of diagnosis
codes. Although no prior study has performed a clinical
validation of the use of ICD-9 and CPT codes to accurately
deﬁne PAD and CLI case rates, the code selection method
described herein could be considered as a common
approach for future analyses.
Finally, the use of the MarketScan database introduces
some bias. The geographic distribution favors the central
and southeastern United States, where CLI risk factors
may be greater. The data for Medicare patients represent
only those patients with supplemental coverage. The data
from commercial insurance only represent employees
from large ﬁrms. The database does not include uninsured
patients.
Table IV. Prevalence of peripheral arterial disease (PAD) and critical limb ischemia (CLI) subgroups overall and by
health insurance plan by year
Group Year
Eligible
population,a
No.
Prevalent PAD or CLI, or both, in total population
PAD,b %
Secondary
CLI,c % Primary CLI,d % Total PAD,e %
Total CLI in
PAD,f %
Overall 2003 1,106,701 11.13 1.20 0.59 12.92 13.84
2004 1,791,587 8.33 0.65 0.43 9.41 11.45
2005 1,952,043 10.39 0.88 0.46 11.73 11.38
2006 1,551,643 12.17 1.01 0.50 13.67 11.02
2007 2,547,638 11.09 0.80 0.45 12.34 10.17
2008 3,030,517 11.01 0.83 0.45 12.29 10.46
Mean
(95% CI)
10.69 (10.67-10.70) 0.86 (0.86-0.87) 0.47 (0.46-0.47) 12.02 (12.00-12.04) 11.08 (11.03-11.13)
Commercial 2003 465,613 6.34 0.52 0.40 7.27 12.70
2004 881,759 5.14 0.32 0.35 5.81 11.53
2005 900,071 5.90 0.39 0.33 6.62 10.87
2006 707,813 5.93 0.37 0.29 6.58 10.01
2007 1,575,641 7.35 0.41 0.35 8.11 9.34
2008 1,961,237 7.28 0.45 0.35 8.09 9.94
Medicaid 2003 287,429 14.54 1.89 0.73 17.16 15.24
2004 310,506 9.81 1.01 0.49 11.30 13.20
2005 426,573 13.76 1.52 0.59 15.87 13.30
2006 382,087 16.27 1.66 0.62 18.55 12.32
2007 300,951 17.50 1.77 0.69 19.97 12.33
2008 306,389 17.66 1.89 0.68 20.23 12.72
Medicare 2003 353,659 14.66 1.52 0.73 16.91 13.33
2004 599,322 12.26 0.93 0.53 13.72 10.65
2005 625,399 14.56 1.13 0.56 16.25 10.40
2006 461,743 18.34 1.45 0.71 20.50 10.54
2007 671,046 16.98 1.29 0.59 18.86 9.98
2008 762,891 17.91 1.40 0.61 19.92 10.08
CI, Conﬁdence interval.
aAdults aged $40 years with commercial, Medicare supplemental, or Medicaid health insurance, from January 1, 2003, through December 31, 2008.
bPAD patients without CLI in a given year, divided by the eligible population in that year.
cPAD patients with a prior PAD diagnostic code or subsequent PAD code #30 days of CLI code in a given year, or both, divided by the eligible population in
that year.
dCLI patients without a prior PAD diagnostic code or subsequent PAD code#30 days of CLI code in a given year, divided by the eligible population in that year.
eSum of PAD, primary CLI and secondary CLI patients, divided by the eligible population in that year.
fTotal number of primary and secondary CLI patients, divided by the total number of PAD patients in that year.
Table V. Risk factors for progression from peripheral
arterial disease (PAD) to critical limb ischemia (CLI),
indicated as secondary CLIa
Risk factor
OR (95% CI)
Univariate Multivariableb
Age at time of
diagnosis
1.007 (1.005-1.009) 1.008 (1.006-1.010)
Male gender 1.153 (1.102-1.208) 1.185 (1.131-1.241)
Diabetes 2.353 (2.237-2.475) 2.331 (2.211-2.458)
Hypertension 0.986 (0.937-1.038) 0.927 (0.880-0.976)
Myocardial
infarction
1.068 (1.020-1.119) 0.942 (0.898-0.989)
Stroke 1.296 (1.228-1.368) 1.217 (1.152-1.285)
Heart failure 1.576 (1.499-1.657) 1.362 (1.292-1.435)
Renal failure 1.336 (1.244-1.435) 0.969 (0.899-1.045)
CI, Conﬁdence interval; OR, odds ratio.
aSecondary CLI deﬁned as a new CLI diagnostic code occurring in a patient
with a pre-existing PAD code or a PAD code occurring #30 days after the
CLI code (n ¼ 15,572).
bThe multivariate model included age and gender as adjustment variables.
Table VI. Risk factors for progression to new critical
limb ischemia (CLI) without peripheral arterial disease
(PAD; primary CLI)a
Risk factor
OR (95% CI)
Univariate Multivariableb
Age at time of
assessment
1.075 (1.074-1.076) 1.051 (1.050-1.052)
Male gender 1.079 (1.048-1.110) 1.075 (1.043-1.107)
Diabetes 19.682 (19.058-20.328) 7.452 (7.191-7.723)
Hypertension 5.081 (4.927-5.240) 2.430 (2.353-2.510)
Myocardial
infarction
6.891 (6.684-7.105) 1.855 (1.792-1.921)
Stroke 8.974 (8.647-9.313) 2.168 (2.083-2.256)
Heart failure 13.929 (13.472-14.402) 2.273 (2.185-2.365)
Renal failure 14.122 (13.479-14.795) 1.866 (1.772-1.965)
CI, Conﬁdence interval; OR, odds ratio.
aPrimary CLI deﬁned as a new CLI diagnostic code occurring in a patient
without a pre-existing PAD code or a PAD code occurring #30 days after
the CLI code (n ¼ 18,251).
bThe multivariate model included age and gender as adjustment variables.
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As the population continues to age, the methods used in
this study could be used to provide population-based surveil-
lance of PAD andCLI and to project health resource utiliza-
tion. Finally, these data could be useful for the planning and
execution of future PADandCLI clinical trials and registries.
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Supplementary Table (online only). International Classiﬁcation of Diseases-9th Revision (ICD-9) and Current
Procedural Terminology (CPT) codesa used to identify peripheral arterial disease (PAD) and critical limb ischemia (CLI)
patients
Category Diagnosis/procedure Associated ICD-9 or CPT codes Frequency of occurrence (%)
PAD diagnosis Other peripheral vascular disease ICD-9: 443.1, 443.22, 443.81,
443.89, 443.9
38.29
Atherosclerosis ICD-9: 440.0, 440.20, 440.21,
440.29, 440.30, 440.31, 440.32,
440.4, 440.8, 440.9
18.02
Diabetes with peripheral circulatory
disorders
ICD-9: 249.70, 249.71, 250.70,
250.71, 250.72, 250.73
8.40
Chronic ulcer of skin ICD-9: 707.06, 707.07 3.18
Other disorders of arteries ICD-9: 447.1 2.99
Atheroembolism ICD-9: 445.02 0.08
CLI diagnosis Pain in limb ICD-9: (729.5)b 4.29
Gangrene ICD-9: 785.4 3.29
Ulcer of lower limb ICD-9: (707.1, 707.10, 707.13,
707.14, 707.15, 707.19, 707.9)b
3.05
Atherosclerosis (with rest pain,
gangrene, or ulceration)
ICD-9: 440.22,440.23,440.24 1.46
Excision/debridement ICD-9: (77.65, 77.66, 77.67,
77.68, 86.22, 99.10)b
0.30
Postoperative wound infection ICD-9: (998.59)b 0.25
Acute osteomyelitis of lower limb ICD-9: (730.06, 730.07)b 0.21
Chronic osteomyelitis of lower
Limb
ICD-9: (730.16, 730.17)b 0.14
Lower extremity
revascularization
Percutaneous transluminal
angioplasty
ICD-9: 00.40, 00.41, 00.42,
00.43, 00.44, 39.50; CPT:
354542, 35454, 35456, 35459,
35470, 35472, 35473, 35474
4.47
Peripheral Bypass ICD-9: 39.25, 39.29; CPT: 35500,
35521, 35533, 35537, 35538,
35539, 35540, 35541, 35546,
35548, 35549, 35551, 35556,
35558, 35563, 35565, 35566,
35583, 35585, 35587, 35621,
35623, 35646, 35647, 35651,
35654, 35656, 35661, 35663,
35665, 35666, 35671, 35681,
35682, 35700, (35683, 35686,
35571)c
1.60
Stents ICD-9: 39.90, 00.45, 00.46,
00.47, 00.48, 00.55
0.85
Other lower extremity
revascularization
ICD-9: 38.08, 39.49; CPT: 35221,
35226, 35256, 35286
0.56
Endarterectomy ICD-9: 38.16, 38.18, 38.38,
38.48, 38.68; CPT: 35302,
35303, 35304, 35305, 35306,
35331, 35351, 35355, 35361,
35363, 35371, 35372, 35381
0.54
Atherectomy CPT: 35480, 35481, 35482,
35483, 35485, 35490, 35491,
35492, 35493, 35495
0.36
Thrombectomy, lower limbs CPT: 35875, 35876, 35879,
35881, 35883, 35884, 35903
0.22
Repair of blood vessel ICD-9: 39.56, 39.57, 39.58 0.04
Lower extremity
amputation
Amputation ICD-9: 84.10, 84.12, 84.14,
84.15, 85.17, 84.3, 84.91
(84.11)b; CPT: 27590, 27591,
27592, 27594, 27596, 27599,
27880, 27881, 27882, 27888,
27889, 28800, 28805, 28810,
28820, 28825
2.12
(Continued on next page)
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Category Diagnosis/procedure Associated ICD-9 or CPT codes Frequency of occurrence (%)
Chronic infection of amputation
stump
ICD-9: (997.62)b 0.10
Disarticulation ICD-9: 84.13, 84.16, 84.18; CPT:
27295, 27598
0.03
aAmerican Medical Association, Chicago, Ill.
bMust be accompanied by one of the following codes: 440.20, 440.21, 440.22, 440.23, 440.24.
cMust be accompanied by one of the following codes: 35556, 35566, 35571, 35583, 35585, 35587, 35623, 35656, 35666, 35671.
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